We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FEBO:NASDAQFenbo Holdings Limited Analysis

Data as of 2026-04-02 - not real-time

$1.14

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Fenbo Holdings trades at $1.14, just below its 20‑day SMA (1.154) and well above the 200‑day SMA (0.946), creating a mixed technical picture. The trend is flagged as bullish, yet the MACD histogram is negative and the signal line is bearish, while volume is on a downtrend and 30‑day volatility spikes above 50%, indicating short‑term pressure. Fundamentally, the company is struggling – revenue fell 36% year‑over‑year, margins are deep in the red (gross 15%, operating –8%, profit –16%) and EBITDA is negative, resulting in a trailing EPS of –$0.20. Despite this, valuation multiples are extremely cheap (price‑to‑sales 0.12, price‑to‑book 2.34) and the DCF model suggests a fair value near $24.6, implying a theoretical upside of over 2,000% if the business could turn around. However, the max drawdown of 55% and a negative beta highlight high market sensitivity and historic price weakness.
Given the stark contrast between the ultra‑low pricing and the deteriorating earnings, investors face a classic high‑risk, high‑potential scenario: the stock is dramatically undervalued on paper but requires a substantive operational recovery to justify any upside.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 4/10

Key Factors

  • Bearish MACD and decreasing volume
  • Price below 20‑day SMA
  • High short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Extremely low price‑to‑sales and price‑to‑book ratios
  • Potential upside if turnaround occurs
  • Continued earnings losses and cash‑flow constraints

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF‑derived fair value far exceeds current price
  • Undervalued relative to peers on valuation multiples
  • Opportunity for strategic restructuring or acquisition

Key Metrics & Analysis

Financial Health

Revenue Growth-36.20%
Profit Margin-16.01%
ROE-34.28%
ROA-10.22%
Debt/Equity61.59
P/B Ratio2.3
Op. Cash Flow$5.5M
Free Cash Flow$20.1M
Industry P/E33.5

Technical Analysis

TrendBullish
RSI48.5
Support$0.91
Resistance$1.30
MA 20$1.15
MA 50$1.13
MA 200$0.95
MACDBearish
VolumeDecreasing
Fear & Greed Index78.8

Valuation

Fair Value$24.62
GradeUndervalued
TypeValue

Risk Assessment

Beta-0.19
Volatility52.37%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.